CYP2D6 genotype information to guide pimozide treatment in adult and pediatric patients: Basis for the US Food and Drug Administration's new dosing recommendations

Journal of Clinical Psychiatry

Volumn 73, Issue 9, 2012, Pages 1187-1190

  Rogers, Hobart L ^a   Bhattaram, Atul ^a   Zineh, Issam ^a   Gobburu, Jogarao ^a,b   Mathis, Mitchell ^a   Laughren, Thomas P ^a   Pacanowski, Michael ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2D6; PIMOZIDE;

ADULT; ARTICLE; CHILD; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG EXPOSURE; DRUG INTERACTION; DRUG LABELING; DRUG METABOLISM; DRUG RESPONSE; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HUMAN; PERSONALIZED MEDICINE; PHARMACOGENOMICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SIMULATION;

EID: 84866479743     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.11m07572     Document Type: Article

References (19)

1. Brown CS, Farmer RG, Soberman JE, et al. Pharmacokinetic factors in the adverse cardiovascular effects of antipsychotic drugs. Clin Pharmacokinet. 2004;43(1):33-56. doi:10.2165/0308-2043010-03 PubMed
2. Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther. 1999;65(1):10-20. doi:10.1016/S09-9236(9)7017-7 PubMed
3. Kang J, Wang L, Cai F, et al. High affinity blockade of the HERG cardiac K(+) channel by the neuroleptic pimozide. Eur J Pharmacol. 2000;392(3):137-140. doi:10.1016/S014-29(0)0123-0 PubMed
4. Shapiro AK, Shapiro E. Controlled study of pimozide vs placebo in Tourette's syndrome. J Am Acad Child Psychiatry. 1984;23(2):161-173. doi:10.1097/04583-1984030-07 PubMed
5. Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry. 1989;46(8):722-730. doi:10.101/archpsyc.1989.01810805206 PubMed
6. Sallee FR, Nesbitt L, Jackson C, et al. Relative efficacy of haloperidol and pimozide in children and adolescents with Tourette's disorder. Am J Psychiatry. 1997;154(8):1057-1062. PubMed
7. Bruggeman R, van der Linden C, Buitelaar JK, et al. Risperidone versus pimozide in Tourette's disorder: a comparative double-blind parallelgroup study. J Clin Psychiatry. 2001;62(1):50-56. doi:10.408/JCP.v62n01 PubMed
8. Gilbert DL, Batterson JR, Sethuraman G, et al. Tic reduction with risperidone versus pimozide in a randomized, double-blind, crossover trial. J Am Acad Child Adolesc Psychiatry. 2004;43(2): 206-214. doi:10.1097/04583-204020- 017 PubMed
9. Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome for tics in Tourette's. Cochrane Database Syst Rev. 2009;(2):CD006996. PubMed
10. Flockhart DA, Drici MD, Kerbusch T, et al. Studies on the mechanism of a fatal clarithromycin-pimozide interaction in a patient with Tourette syndrome. J Clin Psychopharmacol. 2000;20(3):317-324. doi:10.1097/04714-2060-05 PubMed
11. Committee on Safety of Medicines. Cardiac arrhythmias with pimozide (Orap). Curr Prob Pharmacovig. 1995;21(1).
12. Committee on Safety Medicines. Cardiotoxic effects of pimozide. Curr Prob Pharmacovig. 1990;29(11-2):35.
13. Desta Z, Kerbusch T, Soukhova N, et al. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide. J Pharmacol Exp Ther. 1998;285(2):428-437. PubMed
14. Alderman J. Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers. Clin Ther. 2005;27(7):1050-1063. doi:10.1016/j.clinthera.205.07.013 PubMed
15. Gaedigk A, Bradford LD, Marcucci KA, et al. Unique CYP2D6 activity distribution and genotype-phenotype discordance in black Americans. Clin Pharmacol Ther. 2002;72(1):76-89. doi:10.1067/mcp.202.125783 PubMed
16. Nucci G, Muir K, Gomeni R. Population pharmacokinetic modeling of pimozide and its relation to CYP2D6 genotype. Poster presented at the Annual Meeting of Population Approach Group in Europe; June 13-15, 2007; Copenhagen, Denmark.
17. Drolet B, Rousseau G, Daleau P, et al. Pimozide (Orap) prolongs cardiac repolarization by blocking the rapid component of the delayed rectifier potassium current in native cardiac myocytes. J Cardiovasc Pharmacol Ther. 2001;6(3):255-260. doi:10.17/1074248401060306 PubMed
18. Orap (pimozide) 1 mg and 2 mg tablets. Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER). US Food and Drug Administration Web site. http://www.fda. gov/Safety/MedWatch/ SafetyInformation/ucm175823.htm. Updated October 14, 2011. Accessed May 15, 2012.
19. Orap (pimozide) Tablets. US Food and Drug Administration Web site [pdf]. http://www.accessdata.fda.gov/drugsatfda-docs/label/2011/017473s046lbl.pdf. Accessed May 15, 2012.